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Background: Infantile colic is a common paediatric condition which causes significant parental distress. Increased
intestinal coliform colonization in addition to alteration in Lactobacillus abundance and distribution may play an
important role in its pathogenesis.
The objectives of this systematic review are to evaluate the efficacy of probiotic supplementation in the reduction
of crying time and successful treatment of infantile colic.
Methods: Literature searches were conducted of MEDLINE, EMBASE and the Cochrane Central Register of Controlled
Trials. Only randomized controlled trials enrolling term, healthy infants with colic were included. A meta-analysis of
included trials was performed utilizing the Cochrane Collaboration methodology.
Results: Three trials that enrolled 220 breastfed infants met inclusion criteria, of which 209 infants were
available for analysis. Two of the studies were assessed as good quality. Lactobacillus reuteri (strains-American
Type Culture Collection Strain 55730 and DSM 17 938) was the only species utilized in the therapeutic
intervention. Two of the trials were industry funded. Probiotic supplementation compared to simethicone or
placebo significantly and progressively shortened crying times to 7 days reaching a plateau at three weeks post
initiation of therapy [mean difference −56.03 minutes; 95% CI (−59.92, -52.15)]. Similarly, probiotics compared to
placebo significantly increased the treatment success of infantile colic with a relative risk (RR) of 0.06; 95% CI
(0.01, 0.25) and a number needed to treat of 2.
Conclusions: Although L. reuteri may be effective as a treatment strategy for crying in exclusively breastfed
infants with colic, the evidence supporting probiotic use for the treatment of infant colic or crying in formula-fed infants
remains unresolved. Results from larger rigorously designed studies will help draw more definitive conclusions.
Keywords: Infantile colic, Probiotics, Systematic review, Lactobacillus reuteriBackground
Infantile colic is a common problem in healthy thriving
infants that is associated with excessive crying over a
regular period during the day and is sustained for the
first few months of life [1,2]. The condition has been
historically described as irritable or compulsive crying or
paroxysmal fussing with a multifactorial etiology [3]. Al-
though it affects 5% -19% of young infants, [2,4,5] it re-
mains a frustrating problem for parents and care givers
because it is difficult to treat and may result in signifi-
cant psychosocial consequences. A number of cross sec-
tional studies report significant links between infantile
colic and maternal depression and child abuse [6-11].* Correspondence: jasim1800@yahoo.com
1Neonatal Care, Sulaiman Al Habib Medical Group, Arrayan Hospital, P.O. Box
272069, Riyadh 11352, Saudi Arabia
Full list of author information is available at the end of the article
© 2013 Anabrees et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orDespite forty years of research, the etiology of infantile
colic remains elusive. The current literature suggests
several causative mechanisms such as behavioral, food
allergy and hypersensitivity, immaturity of gut function
and dysmotility [12-14]. Of note, Shenassa et al. through
a comprehensive review of 5 studies identified a possible
link between maternal smoking and infantile colic which
may be mediated through increased plasma and intestinal
motilin levels [15]. Recently, the composition of intestinal
microbiota has been addressed as an independent risk fac-
tor for infantile colic [16-18]. Studies indicate that inad-
equate lactobacilli in the first few months of life may
affect intestinal fatty acid profile favoring the development
of infantile colic [16,17]. Coliform bacteria have also been
found more abundantly in colicky infants and it is specu-
lated that altering the intestinal microbiota composition
may positively influence the management of affected in-
fants [19]. In practice, the only probiotic used for infantileal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ture Collection Strain 55730 or DSM 17 938). However,
other Lactobacillus species such as L.delbrueckii subsp.
delbrueckii DSM 20074 and L. plantarum MB 456 have
proven inhibitory activity against gas-forming coliforms
and may play a significant role in the management of in-
fantile colic [20]. Similarly, Aloisio et al. evaluated four
Bifidobacterium strains, namely, B. breve B632 (DSM
24706), B2274 (DSM 24707), B7840 (DSM 24708), and B.
longum subsp. longum B1975 (DSM 24709), and found
that they may be potentially useful for the treatment of in-
fantile colic or as a preventive strategy for infantile
bacterial-related diarrhea [21]. However, exploratory clin-
ical trials investigating both the safety and efficacy of pro-
biotics incorporating these species are yet to be conducted.
The objectives of this systematic review are to evaluate
the efficacy of probiotic supplementation in the reduc-




Eligible studies were identified from OVID MEDLINE –
National Library of Medicine [January 1966 to Septem-
ber 2012] using the following subject MeSH headings
and text word terms: neonate(s), newborn(s), infant(s),
probiotics, lactobacillus, bifidobacterium, colic; publica-
tion type was limited to controlled trials. No language
restriction was applied. Other databases were also searched
including: EMBASE (January 1980 to September 2012) the
Cochrane Central Register of Controlled Trials (CEN-
TRAL, the Cochrane Library, Issue 9, 2012). Additional ci-
tations were sought using references in articles retrieved
from searches. Content experts were contacted to identify
unpublished and ongoing studies.
Study selection
We included all randomized or quasi-randomized con-
trolled trials that compared probiotics (any dose or com-
position) to placebo, control or other forms of treatment
in healthy full term infants with infantile colic who were
less than 4 months of age. All definitions of infantile
colic were deemed acceptable. We considered articles in
any language as long as there was an abstract in English
indicating content.
Data extraction
Retrieved articles were assessed for eligibility, and two
reviewers independently abstracted descriptive data on
the subjects, type of intervention, infants allocated as
control, outcomes and methodological quality of the ar-
ticles. Discrepancies were resolved by discussion and
consensus. Where data were incomplete, the principalinvestigator of the primary study was contacted for fur-
ther information and clarification.
Methodological quality of the studies
Standard methods of the Cochrane Collaboration [22]
were used to assess the methodological quality of included
trials. For each trial, information was sought regarding the
method of randomization, allocation concealment, blind-
ing, and completeness of follow up and on reported
outcomes of all infants enrolled in the trial. The meth-
odological details of the studies were extracted from
published data and by contacting the primary author
where possible.
Data synthesis
The primary outcome was treatment success, defined as
the percentage of children who achieved a reduction in
the daily average crying time >50%. The secondary out-
comes were duration of crying (minutes per day) and ad-
verse events related to probiotic supplementation. For
dichotomous outcomes, relative risk (RR) and its associ-
ated confidence interval were calculated. For continuous
outcomes, treatment effect was expressed as mean dif-
ference and its calculated standard deviation. Meta-
analysis of pooled data was performed using a fixed
effects model with the assumption that L. reuteri DSM
17938 and L. reuteri ATCC 55730 are bioequivalent and
the added recognition that the comparison groups were
simethicone (one trial) or placebo (two trials). Review
Manager (RevMan), Version 5.2 software was used for
statistical analysis. A subgroup analysis was planned a
priori to investigate the effect of probiotics in subjects
with a positive family history of atopy, and additionally
on different strains of probiotics utilized. Heterogeneity
was defined as a significant test when the p value was <
0.1 and/or if similar differences were identified in treat-
ment effects across studies. Tests for between-study het-
erogeneity (including the I2 test) were performed.
Since included studies expressed their primary outcome
(crying times) as median (range or interquartile range), in
order to statistically pool the data and perform a meta-
analysis, this outcome was converted into mean (standard
deviation) as recommended by Hozo et al. [23].
Results
A total of 10 potentially relevant citations were obtained
through our primary search strategy (Figure 1). Seven
studies were excluded because the investigators used
probiotic based formulae in non-colicky neonates, which
undermined the primary objectives of the meta-analysis.
Three trials met our inclusion criteria [24-26]. Although
Szajewska et al. [26] planned an inclusion criterion of in-
fants aged less than five months, the actual maximum
age at enrolment was 81 days. Characteristics of the


























n Additional studies identified through 
other sources 
(n = 0)





147 studies excluded for the 
following reasons:
Review articles (n= 48)
Prebiotics included (n=26)
Infant formula used (n=22)




because probiotic based 
formulae were used in non-
colicky neonates 
(n = 7)
Studies included in 
qualitative analysis
(n = 3)
Studies included in 
quantitative meta-analysis
(n = 3)
Full-text articles assessed for 
eligibility 
(n = 3)
Figure 1 PRISMA flow diagram 2009 of included studies.
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going trials are summarized in Table 2, but the data
since incomplete were not included in this review.
Overall, 140 infants were exclusively breastfed [24,25]
while Szajewska et al. additionally reported that 80 of
the infants in their trial were exclusively or predomin-
antly (>50%) breastfed [26]. In general, included trials
had a low risk of bias (Table 3). A total of 209 healthy
infants were enrolled across the three studies and most
of the infants were exclusively breast fed. All of the clinical
trials utilized the same probiotic species (Lactobacillus
reuteri; strains-American Type Culture Collection Strain
55730 or DSM 17 938) with identical daily doses. One
study evaluated the efficacy of probiotic supplementation
against simethicone [24]. None of the included studies re-
ported any adverse side effects of supplementation.Effect of L. reuteri on crying time
The effect of L. reuteri on crying time was compared to
simethicone or placebo. Data on crying time were re-
ported by all three trials as a primary outcome and in-
volved 209 infants. At seven days after initiation of
treatment, infants in the probiotic group had a signifi-
cantly shorter crying time. The crying time at 7 days was
significant only in the fixed effects model, but was insig-
nificant in the random effects model. However, the treat-
ment effect was continuous and stabilized at three weeks
following the initiation of therapy. Probiotics decreased
crying times by almost one hour [mean difference −
56.03 minutes; 95% CI (−59.92, -52.15)] (Figure 2). In
order to reduce heterogeneity and the potential effect of
simethicone, a sensitivity analysis on only the double-
blind, placebo-controlled, trials [24,26] was conducted.
Table 1 Characteristics of trials included in the analysis
Study/year/reference Description/study design Birth weight and age at
enrolment
Probiotic agent(s) Dosage and duration Control arm Primary outcome
Savino/2007 [24] April 2004 - May 2005. Birth weight 2500-4000 g
and aged 21–90 days
L. reuteri (American Type Culture
Collection Strain 55730)
108 colony-forming units in 5
drops for 28 days
Simethicone A reduction of average
crying time to less than
3 hours a day on day 28.90 exclusively breastfed infants
with a diagnosis of
infantile colic.
Recruited in the Department
of Pediatric and Adolescence
Science (Regina Margherita
Children Hospital, Turin, Italy)
Open prospective
randomized study.
Savino/2010 [25] March 2008 and August 2009. Birth weight 2500–4000 g
and aged 2–16 weeks
L. reuteri DSM 17938 108 colony-forming units in 5
drops, once a day, 30 minutes
before the feed in the morn-
ing, for 21 days
Placebo A reduction of average
crying time to less than
3 hours a day on day 21.50 exclusively breastfed infants
were recruited from general
pediatricians and outpatients
at the Department of









L. reuteri DSM 17938 108 colony-forming units in 5
drops, orally, once a day, for
21 days
Placebo The percentage of children
achieving a reduction in
the daily average crying
time more than 50% and
the duration of crying at 7,



























Table 2 The ongoing trials of probiotics and infant colic
No Study Inclusion and exclusion criteria Primary outcome Estimated
enrollment
Arms
1 Effect of L. rhamnosus GG (LGG)
on Infant Colic
Inclusion Criteria: Crying times of infants 60 Experimental: Nutramigen
Lipil with Enflora
Sixty healthy full-term colicky infants




Diarrhea (stools that take the shape
of a container > 5x daily)
Fever
2 Control of Colic in Infants by
Dietary Supplementation with
the Probiotic L. reuteri
Inclusion Criteria: Reduction of daily average
crying time to less than
3 hours from baseline
50 Experimental: L. reuteri
Infants aged between 14–60 days Control: Not clear
Breast fed, exclusively during length
of trial
Diagnosis of infantile colic according
to Wessel’s criteria
Debut of colic symptoms 6 ± 1 days
before randomization
Gestational age between 37–42 weeks
Apgar score higher than 7 at 5 minutes
Mothers willing to follow a cow milk-
free diet during the study period
Written informed consent and stated
availability throughout the study period
Exclusion Criteria:
Major chronic disease
Gastrointestinal disease but controlled
gastroesophageal reflux disease
Administration of antibiotics the
week before randomization
Administration of probiotics the week
before randomization
Participation in other clinical trials
3 Baby Biotics randomised
controlled trial
Inclusion criteria Infant crying/fussing time 160 Experimental: L. reuteri
DSM 17938.
Infant colic as defined by the
modified Wessel’s criteria
(min/day)
Less than 3 months Control: maltodextrose
Greater than 36 weeks gestation
at birth




Taking solids, antibiotics or L. reuteri
and, if breastfeeding, mother taking
L. reuteri at the time of study
commencement;
Cow’s milk protein allergy
Caregiver has insufficient English to
understand informed consent and
complete questionnaires.
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Savino/2007 [24] Low risk Low risk High risk Low risk Low risk Low risk Low risk
Savino/2010 [25] Low risk Unclear risk Low risk Low risk Low risk Low risk Low risk
Szajewska/2013 [26] Low risk Low risk Low risk Low risk Low risk Low risk Low risk
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similar reduction in crying time at 21 days [mean differ-
ence −55.48 minutes; 95% CI (−59.46, -51.49)].
Effect of L. reuteri on overall response rate
The overall response rate of L. reuteri was compared to
simethicone or placebo. Responders (or treatment suc-
cess) was defined as the percentage of infants achieving
a reduction in the daily average crying time of more than
fifty percent. The response rate was reported in two of
the trials at each assessment interval. Savino et al. re-
ported the response rate at 28 days only [24]. A progres-
sive, statistically significant response was noted starting
at 7 days [25] after initiation of therapy (Figure 3). The ef-
fect was maximal at 21 days following the commencement
of treatment, with a relative risk (RR) of 0.06; 95% CI
(0.01, 0.25) and a number needed to treat (NNT) of 2. Of
note, a similar progressive improvement was also evident
in the control subjects; however, the positive effect was
more pronounced in the probiotic group.
Effect with a history of atopy
The impact of atopy was documented in only one study
[26]. A concomitant history of atopy did not alter the ef-
ficacy of probiotics in treated infants.
Discussion
We report the first systematic review of randomized
trials addressing the efficacy of probiotics in infantile
colic. A significant effect of L. reuteri supplementation
(strains-American Type Culture Collection Strain 55730
and DSM 17 938) in shortening crying times and improve-
ment in response rate was noted. This positive response
was progressive with time and had its peak and plateau at
three weeks after initiation of therapy. A similar positive
effect was noted in the control group, which could be ex-
plained, by the natural history of infantile colic or a pla-
cebo effect [22,23]. However, the effect in the probiotic
group was more pronounced. It is important to note that
one of the strains (L. reuteri ATCC 55730) used in one of
the included trials [24] was found to carry potentially
transferable resistance traits for tetracycline and lincomy-
cin in adults [27] and was replaced in subsequent studiesby L. reuteri DSM 17938, a daughter strain that retained
the original probiotic characteristics [28,29].
Our systematic review included currently available,
high quality studies. However; our overall conclusion is
compromised by the small number of enrolled infants
despite the common prevalence of infantile colic, and
the heterogeneity of included studies that assessed cry-
ing time. This heterogeneity can be explained by the
clear imbalance of both groups at baseline, in the study
reported by Savino et al. [25]. The probiotic group
started with significantly longer crying times that
quickly moved to a profoundly positive benefit after
7 days of treatment. Most of the included subjects were
exclusively breast fed which limits the generalizability of
the findings to formula fed infants. However, the incidence
of colic in breast and bottle fed infants is similar [30] be-
cause the pathogenesis of the disorder is likely multifac-
torial and the use of probiotics may be influential in the
treatment of colic by altering faecal microbiota and gut in-
flammation irrespective of feeding patterns [16-19,31].
The earlier trial by Savino et al. [24] involved the use
of simethicone in the placebo arm. This may have de-
creased the magnitude of the effect of probiotics unless
the effect of simethicone was not indifferent to placebo.
The sensitivity analyses confirmed that the inclusion of
the simethicone treated patients in this study did not
significantly impact heterogeneity or the crying time at
21 days. One well recognized limitation of all studies on
infant colic is the need for a more objective way of
measuring duration of crying rather than relying on the
parents’ compliance to establish this outcome. Computer
recordings of crying episodes comprise a more concrete
form of assessment and should be considered for future
studies. Two of the included trials were supported by the
manufacturer of the probiotic strain under study, which
raises the possibility of bias. However, the likelihood is
small since the trials were fully investigator-initiated and
data controlled with transparent disclosure of potential
conflicts of interest by the respective authors [32,33].
Recently few studies have addressed the role of changing
intestinal microbiota in the pathogenesis of colic. Colicky in-
fants were found to have increased colonization by coliforms
especially E.coli and decreased and altered colonization
Figure 2 Forest plot of L. reuteri ATCC 55730 and L. reuteri DSM 17938 versus control effect in decreasing mean crying times (min)
over 28 days.
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reuteri also exerts an antimicrobial effect against enteric
pathogens which may induce an immunologic response
[34-36]. Immune modulation could also play a role in the ef-
ficacy of probiotics in infantile colic as it may represent the
first sign of food hypersensitivity [37]. Since probiotic sup-
plementation appears to require time to exert an effect in
colicky infants, it would be interesting to evaluate its efficacy
as a prophylactic treatment after birth. It’s unclear whether a
similar or cumulative effect would be observed if other for-
mulations of probiotic bacteria are utilized either alone or in
combination with the same strains of L. reuteri.Conclusions
Our review supports the beneficial effects of probiotic
supplementation in infantile colic in predominantly
breast fed infants. L. reuteri (strains-American Type Cul-
ture Collection Strain 55730 and DSM 17 938) signifi-
cantly decreased the rate (minutes/day) of crying and no
short term safety concerns were identified. However, all
three included studies demonstrate a positive outcome
which may be a reflection of the relatively small, com-
bined, sample size that overshadows the true effect
which may be realized in a single, large-scale, multicen-
ter, randomized trial. More independent studies are still
Figure 3 Forest plot of L. reuteri ATCC 55730 and L. reuteri DSM 17938 versus control effect in improving infantile colic treatment
success rate over 28 days.
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mula fed infants, [38] prior to adopting a change in
practice.
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